Saturday, November 21, 2026

Subscribe

NewsEdition Guinea-BissauGuinea-Bissau

Guinea-Bissau newborn trial reignites debate over ethics and vaccine protection

A research project involving 14,000 infants in Guinea-Bissau has received fresh approval after being suspended for ethical review. The vaccination schedule and protection for newborns remain at the heart of the debate.

Health professionals and members of an ethics committee meet in Bissau around a newborn vaccination file.

For families in Bissau and rural areas, the first weeks of a child’s life could become the focus of a debate that goes far beyond medical research: who decides the level of protection offered to newborns, and under what rules? A hepatitis B trial, contested for several months, has just reached a new stage, although questions over its authorisation and start have not all been resolved.

Vaccination schedule at the heart of the debate

In Guinea-Bissau, hepatitis B vaccination currently begins at around six weeks, as part of the existing infant immunisation schedule. This gap with the international recommendation forms part of a policy the country plans to change: the authorities decided in 2024 to add a dose given at birth, with its introduction announced by 2028. Guinea-Bissau is a member of ECOWAS, the West African regional organisation for political and economic cooperation; it also takes part in continental public health work led by the African Union and Africa CDC.

The World Health Organization recommends that all newborns receive their first dose of hepatitis B vaccine as soon as possible, ideally within 24 hours of birth. This dose aims in particular to reduce the risk of transmission from mother to child. It is followed by further doses during early childhood. WHO sets out its recommendation on vaccination at birth.

The issue is particularly sensitive in the country. A survey published in a medical journal and indexed by the US National Library of Medicine estimated the prevalence of hepatitis B among adults in Bissau at 18.7%. This result concerns a local survey, not the entire national population; it nevertheless gives an indication of the presence of the virus in the capital. The study on hepatitis B among Bissau’s adult population.

Large-scale protocol, contested authorisation

The project is led by Danish researchers affiliated with the University of Southern Denmark and the Bandim Health Project, a research programme based in Bissau. It plans to follow up to 14,000 infants. In the experimental group, children would receive a dose at birth; in the other group, the first hepatitis B dose would be given at around six weeks, in line with the current schedule. The protocol aims to measure the effects of early vaccination on children’s health.

The plan was suspended by the Guinea-Bissau authorities in January 2026 pending a fresh ethical review. The decision followed questions about the validity of the initial assessment. The health minister said at the time that, in his view, the national ethics committee had not reviewed the study under the required conditions. Africa CDC, the African Union’s public health agency, backed a further review. The report on the suspension announced in January.

On 7 October, the dean of the Danish university’s faculty of health sciences gave the researchers the go-ahead to proceed with the revised project. Reports published on 9 October also say that officials in Guinea-Bissau have given the green light. However, available accounts do not all describe the scope of this decision in the same way: approval from the Danish institution is not, by itself, enough to establish that all national authorisations have been definitively secured or that recruitment has begun. Ethical approval, administrative authorisation and the actual launch of the trial must be distinguished. The latest reports on the go-ahead for the revised protocol.

Consent and protection

The researchers defend the study by pointing out that the birth dose is not yet routinely administered in the country. The protocol would therefore compare the new strategy with the schedule currently in use. But this argument does not end the debate: an existing practice does not automatically answer the question of whether delaying vaccination is acceptable when a WHO recommendation calls for earlier protection.

The controversy also concerns the quality of parental consent, the health system’s capacity to screen mothers and provide follow-up, and how risks and benefits are distributed. The revised version of the protocol would include hepatitis B screening for pregnant women. Screening reduces some risks, but does not eliminate them entirely: a negative result alone cannot guarantee that a maternal infection has been ruled out.

The effects would not be the same for all families. In Bissau’s maternity wards, teams may be better placed to offer screening and follow-up. In rural areas, access to antenatal care and continuity of visits may be more difficult. For parents, the immediate issue is to understand which group their child might be assigned to and what protections would be offered. For healthcare workers, the study would add follow-up requirements to an already overburdened system.

The project’s US funding, reported at $1.6m, is also contributing to questions. US Health Secretary Robert F. Kennedy Jr. has publicly praised the researchers, amid changes and debate over US vaccine policy. This political association is fuelling mistrust; it is not, however, in itself evidence of the protocol’s scientific validity. The discussion should therefore focus on verifiable elements: methods, consent, independent monitoring and participants’ access to care.

A test of health governance for the region

Beyond the trial itself, the central question is Guinea-Bissau’s ability to set the conditions for research conducted with foreign partners. Independent review, transparent authorisations and the representation of Guinea-Bissauan researchers and healthcare professionals will be crucial to public trust. National authorities cannot be reduced to hosts of a project designed elsewhere: they must be able to amend, suspend or reject it.

The next step to watch is therefore concrete: publication of the updated protocol and formal decisions by the Guinea-Bissau authorities, followed by confirmation of any planned recruitment date. Until these elements are clearly established, it would be premature to say that a trial has already begun. For Guinea-Bissau, as for other ECOWAS countries, this case raises a lasting question: how can local research be developed while ensuring that participant protection standards do not vary according to the country in which a study takes place?

Automatic translation. Original French version

The quiz

Edition Guinea-BissauGuinea-Bissau in 5 questions

5 questions